Outcome Determinants of Commercial Car‐t Cell Therapy for Large B‐cell Lymphoma: Results of the Gla/DRST Real World Analysis

Dreger, Peter; Martus, Peter; Ayuk, Francis A.; Wagner-Drouet, Eva; Wulf, Gerburg M.; Marks, Reinhard; Penack, Olaf; Koenecke, Christian; Bonin, Malte von; Tresckow, Bastian von; Stelljes, M.; Baldus, Claudia D.; Vučinić, Vladan; Mougiakakos, Dimitrios; Topp, Max S.; Wolff, D. A.; Schroers, Roland; Schmitt, M.; Schmitt, Thomas; Lengerke, Claudia; Thomas, S.R.; Beelen, Dietrich W.; Bethge, Wolfgang

doi:10.1002/hon.186_2880

Search citation statements

Order By: Relevance

Paper Sections

Select...

(See Table II and Table Iii)1

Ongoing Trials Of Cd19 Car-t Cell1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Real-world data do not currently exist for liso-cel owing to its very recent approval. Authors from the German Register for Stem Cell Transplantation (DRST) presented a first risk factor analysis of standard-of-care (SOC) CAR-T cell therapies for DLBCL (27). A total of 267 patients were included, who received axi-cel (137) or tisa-cel (130) for treatment of DLBCL until December 2020.…”

Section: (See Table II and Table Iii)mentioning

confidence: 99%

See 1 more Smart Citation

Car T Cell Therapy. A New Milestone in the Treatment of B Cell Lymphomas

Nizzoli¹,

Bavieri²,

Luminari³

2022

Ann Res Oncol

View full text Add to dashboard Cite

show abstract

Section: (See Table II and Table Iii)mentioning

confidence: 99%

“…Vol. 2(1), [21][22][23][24][25][26][27][28][29][30][31][32][33]2022 SCEND-CLL-044 is assessing CAR-T cell therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (NCT03331198).…”

Section: Ongoing Trials Of Cd19 Car-t Cellmentioning

confidence: 99%